ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ivosidenib

Also written as “Ivosidenib”, “Ivosidenib Oral Tablet” and “AG120”.

Its studies are mostly in Cholangiocarcinoma · Leukemia, Myeloid, Acute · Neoplasm Metastasis · Neoplasms, Unknown Primary, led by 6 companies.

Drug pageIvosidenib: every studyMany companies study it; this page follows only the 13 they lead. All 55 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jul 1, 201513 company-led studies, 5 open or runningNext primary completion: Oct 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agios Pharmaceuticalsits history only50 open or runningphase 1since Jul 1, 2015Jul 1, 2015none ahead
Servier Bio-Innovation32 open or runningphase 3since Nov 7, 2023Apr 21, 2023Feb 1, 2028phase 3 · NCT06127407
Servier Affaires Médicalesits history only22 open or runningphase 3since May 17, 2023May 17, 2023Oct 15, 2027phase 3 · NCT05907057
CStone Pharmaceuticalsits history only10 open or runningphase 1since Oct 29, 2019Oct 29, 2019none ahead
Hoffmann-La Rocheits history only10 open or runningphase 2since Apr 5, 2018Apr 5, 2018none ahead
Servierits history only11 open or runningphase 2since Sep 14, 2023Sep 14, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2015Named ivosidenibINNProposed as its International Nonproprietary Name in WHO's List 114 · before, AG120
  2. Apr 21, 2023First study: phase 2 study in IDH1-mutant CholangiocarcinomaFirst studyNCT05921760 · 7 enrolled · United States, United Kingdom
  3. Nov 7, 2023Phase 3 study in Neoplasm MetastasisNCT06127407 · 156 planned · United States, Australia, Belgium and more
  4. May 27, 2025Phase 1 study in IDH1-Mutated MalignanciesNCT07006688 · 30 planned · United States, Australia, Brazil and more

Ahead

  1. Feb 1, 2028Primary completion: phase 3 study in Neoplasm MetastasisNCT06127407
  2. Jul 31, 2028Primary completion: phase 1 study in IDH1-Mutated MalignanciesNCT07006688

TargetBeta

IDH1 →read by rule
“An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), ”NCIt, by rule
“Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor”ChEMBL 37, by rule

Other programs on IDH1

ProgramCompanyFurthest phaseStudies
olutasidenibruleRigel Pharmaceuticalsphase 45
vorasidenibruleAgios Pharmaceuticalsphase 312
ranosidenibruleHUTCHMEDphase 37
safusidenibruleNuvation Biophase 36
IDH1 Inhibitor TQB3454Sino Biopharmaceuticalphase 35

Studies

All 3 Servier Bio-Innovation leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07006688IDH1-Mutated Malignancies · United States, Australia, Brazil and more1RecruitingJul 31, 202830
NCT06127407Neoplasm Metastasis · United States, Australia, Belgium and more3RecruitingFeb 1, 2028156
NCT05921760IDH1-mutant Cholangiocarcinoma · United States, United Kingdom2TerminatedNov 21, 20247

How it is read

Names in the registry

  • “Ivosidenib”, 3 entries
  • “Ivosidenib Oral Tablet”, 2 entries
  • “AG120”, 2 entries
  • “Ivosidenib 500mg”, 1 entry
  • “Ivosidenib 500mg Oral Tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.